



St Mary's
University
Twickenham
London



Iron Deficiency and the Endurance Athlete

Richard Burden
St Mary's University

BBTS Annual Conference 2014



Doping






EPO

Effect of rhEPO administration on serum levels of sTfR and cycling performance

KÅRE I. BIRKELAND, JIM STRAY-GUNDERSEN, PETER HEMMERSBACH, JOSTEIN HALLEN, EGIL HAUG, and ROALD BAHR

Hormone Laboratory, Aker University Hospital and Norwegian University of Sport and Physical Education, Oslo, NORWAY



Eur J Appl Physiol (2002) 86: 442–449
DOI 10.1007/s00421-001-0560-6

ORIGINAL ARTICLE

Gabrielle Russell · Christopher J. Gore
Michael J. Ashenden · Robin Parisotto · Allan G. Hahn


Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise

- IV and oral iron increase the effect of EPO
- IV more effective than oral



EPO Abuse?


Schumacher & Pottgeisser (2004)



5 000m


♂

- Current elite athletes intentionally used doping?
 - 14-39% (de Hon et al., 2014)



10 000m


♂




Zotter et al. (2004)



Maximal Aerobic Capacity ($\text{VO}_{2\text{max}}$)



- A key determinant of successful endurance performance
- Highly correlated with Hb-mass





Iron Deficiency and Endurance Athletes

- Endurance athletes more susceptible to greater iron losses
- Iron deficient anaemia (IDA) vs. iron deficient non-anaemia (IDNA)
 - IDA reduces aerobic capacity (Garvican et al., 2011)
 - IDNA is less clear
- Does IDNA exist?



A Case Study of an Iron-Deficient Female Olympic 1500-m Runner

Charles R. Pedlar, Gregory P. Whyte, Richard Burden, Brian Moore,
Gill Horgan, and Noel Pollock






Figure 1 — Ferritin values (open squares) and 1500-m-running time (min:s; closed diamonds) during the period studied. The 2 highest serum ferritin values (>35 g/dL) occurred after iron injections, and the lowest values (<20 g/dL) corresponded with peak training volumes, often preceding major championships. Linear trend lines of best fit are shown (upper line: $r^2 = .92$ for annual personal best; lower line: $r^2 = .02$ for sFe). X's denote the treadmill tests (data are presented in Figure 2) and +'s represent iron injections.



Impact of intravenous iron on aerobic capacity and iron metabolism in elite athletes

- 15 IDNA (< 30.0 µg/L, Hb > 12.0 g/dL)
 - female $n = 9$, Male $n = 6$
- Randomised control trial
 - IG - 500 mg intravenous iron injection (ferric carboxymaltose)
 - PG - 0.9% sterile saline solution
- 3 x discontinuous exercise tests to exhaustion
 - Pre-treatment
 - 24 h post-treatment
 - 4 wks post-post treatment
- Iron studies
 - Pre-test
 - Immediately post-test
 - 3 h post-test
 - sFer, sFe, Tsat, sTfR, sTf, IL-6, Hepcidin
- Total haemoglobin mass








Ferritin ($\mu\text{g L}^{-1}$)

Iron

m. Post Exercise 3 hr Post Exercise Pre Exercise Imm. Post Exercise 3 hr Post Exercise Pre Exercise Imm. Post Exercise 3 hr Post Exercise
Exercise Pre-Treatment 24 h Post Treatment 4 wk Post-Treatment



Placebo




24 h Post-Treatment


4 wk Post-Treatment



Iron




Placebo






Iron



Placebo





Impact of intravenous iron on aerobic capacity and iron metabolism in elite athletes

- IV iron injections increase ferritin
- No change
 - aerobic capacity
 - Hb mass
 - Red cell indices
- Iron availability, not inflammation mediates the hepcidin response following iron treatment
- So where they iron deficient?




Questions Raised

- Target indicators
 - Ferritin






Ferritin






Ferritin






Ferritin





Questions Raised

- Are current indicators appropriate?
 - Ferritin
 - Hepcidin?
- Sensitivity of assessment tools
- Long-term effects of low iron
- IDNA does not exist but...





St Mary's
University
Twickenham
London

THANK YOU



References


- de Hon O, Kuipers H & van Bottenburg M. (2014). Prevelence of doping use in elite sports: A review of umbers and methods. *Sports Medicine*.
- Zotter H, Robinson N, Zorzoli M, Schattenberg L, SaugyMP & Mangin P (2004). Abnormally high serum ferritin levels among professional road cyclists. *British Journal of Sports Medicine*, 38, 704-708
- Schimacher YO & Pottgiesser T (2009). Performance profiling: A role for sport science in the fight against doping. *International Journal of Sports Physiology and Performance*, 4, 129-133.



The efficacy of iron treatment for endurance athletes: A meta-analysis

Ferritin

Hedges' $g = 1.068$ (large effect)




$\text{VO}_{2\text{max}}$

Hedges' $g = 0.610$ (moderate effect)

		Hedges' g		Hedges' g
Peeling et al. 2007 (20)	Injection	0.519	Peeling et al. 2007 (20)	Injection
Hinton et al. 2000 (21)	Oral	2.094	Hinton et al. 2000 (21)	Oral
Friedman et al. 2001 (84)	Oral	0.148	Friedman et al. 2001 (84)	Oral
Hinton & Sinclair, 2007 (42)	Oral	0.026	Hinton & Sinclair, 2007 (42)	Oral
Klingshirn et al. 1992 (66)	Oral	0.141	Klingshirn et al. 1992 (66)	Oral
Bleu et al. 1999 (10)	Injection	0.064	Bleu et al. 1999 (10)	Injection
Zhu & Haas, 1998 (28)	Oral	0.098	Zhu & Haas, 1998 (28)	Oral
Magazanik et al. 1991 (21)	Oral	2.073	Magazanik et al. 1991 (21)	Oral
Magazanik et al. 1991 (42)	Oral	0.572	Magazanik et al. 1991 (42)	Oral
LaManca et al. 1993 (68)	Oral	1.993	LaManca et al. 1993 (68)	Oral
Fogelholm et al. 1992 (56)	Oral	0.261	Fogelholm et al. 1992 (56)	Oral
Radjen et al. 2011 (35)	Oral	0.318	Radjen et al. 2011 (35)	Oral
Walsh & McNaughton, 1989 (84)	Oral	1.493	Walsh & McNaughton, 1989 (84)	Oral
Schoene et al. 1983 (14)	Oral	0.197	Schoene et al. 1983 (14)	Oral
DellaValle & Haas 2013 (42)	Oral	0.196	DellaValle & Haas 2013 (42)	Oral
Total		0.610	Total	0.610




Hepcidin






Iron




Placebo






Hepcidin






Hepcidin






Hepcidin





Hepcidin





Measure	Group	Pre-Treatment			24 Hours Post-Treatment			4 Weeks Post-Treatment		
		Pre	24 h Post	4 wks Post	Pre	24 h Post	4 wks Post	Pre	24 h Post	4 wks Post
Serum Iron, umol·L ⁻¹	IG	20.3 (7.2)	23.2 (8.2)	20.6 (9.5)	70.7*† (10.0)	72.8*† (8.5)	64.0*† (11.9)	23.4 (4.0)	25.7 (3.3)	21.2 (4.9)
	PG	19.3 (6.9)	22.5 (7.3)	21.8 (8.0)	20.6 (14.3)	23.4 (15.5)	21.3 (11.9)	15.1 (6.2)	17.9 (9.0)	17.3 (6.9)
	IG	33.1 (12.0)	34.3 (13.9)	32.4 (15.0)	113.2*† (8.4)	110.6*† (6.9)	104.7*† (5.9)	43.2 (6.3)	45.1 (6.0)	39.2 (8.4)
	PG	29.1 (11.3)	31.2 (11.8)	31.4 (12.6)	30.3 (19.7)	31.5 (19.6)	30.9 (17.4)	20.9 (11.2)	24.8 (12.0)	24.8 (10.5)
Tsat, %	IG	2.5 (0.3)	2.7 (0.2)	2.6 (0.2)	2.5 (0.3)	2.6 (0.3)	2.4 (0.4)	2.2 (0.4)	2.3 (0.3)	2.2 (0.3)
	PG	2.7 (0.4)	2.9 (0.4)	2.8 (0.6)	2.8 (0.5)	3.0 (0.4)	2.8 (0.4)	2.7 (0.4)	2.9 (0.4)	2.8 (0.4)
	IG	19.4 (2.9)	21.2 (2.1)	19.6 (2.8)	20.4 (3.1)	21.3 (2.2)	20.3 (3.1)	19.4 (2.6)	19.9 (2.4)	19.0 (2.4)
	PG	23.2 (3.0)	23.4 (2.1)	21.8 (2.5)	21.4 (2.7)	23.1 (3.1)	21.3 (3.1)	22.1 (2.1)	23.4 (2.8)	22.1 (2.0)



	Placebo Group		Iron group	
	Pre	4 wks Post	Pre	4 wks Post
Haemoglobin, g·L ⁻¹	143.6 (9.0)	138.7 (11.7)	140.2 (15.4)	137.2 (13.8)
Haematocrit, L·L	0.426 (0.021)	0.406 (0.024)	0.415 (0.032)	0.414 (0.025)
Mean Cell Volume, fL ⁻¹	89.13 (3.72)	88.29 (2.75)	90.27 (4.46)	92.98 (5.95)
Mean Cell Hb, pg	30.01 (1.37)	30.06 (1.28)	30.38 (1.59)	30.70 (1.51)
Mean Cell Hb Conc, g·L ⁻¹	337.25 (8.38)	341.29 (11.59)	337.17 (13.93)	330.83 (15.14)
RDW, %	13.08 (0.78)	13.04 (0.68)	12.70 (0.68)	12.92 (0.58)
Red Cell Count, 10*12·L ⁻¹	4.7938 (0.3046)	4.6171 (0.3541)	4.6083 (0.4271)	4.4750 (0.4428)
Red Cell Folate, µg·L ⁻¹	269.63 (133.51)	245.19 (118.18)	265.70 (110.41)	238.42 (67.22)
B12, ng·L ⁻¹	482.75 (117.66)	476.29 (172.44)	567.00 (175.03)	573.00 (175.87)



	Placebo Group			Iron Group		
	Pre Treatment	24 h Post Treatment	4 wks Post Treatment	Pre Treatment	24 h Post Treatment	4 wks Post Treatment
tHb, g·kg ⁻¹	12.15 (1.53)	12.16 (1.84)	12.43 (2.10)	14.13 (1.93)	13.88 (1.77)	13.12 (1.72)
VO _{2max} , ml·kg ⁻¹ ·min ⁻¹	64.40 (10.22)	64.83 (9.56)	64.27 (7.35)	73.02 (4.80)	71.60 (6.78)	70.30 (5.29)
Economy, ml·kg ⁻¹ ·km ⁻¹	220.13 (3.14)	216.63 (10.02)	215.29 (10.11)	221.33 (6.12)	217.00 (9.83)	218.00 (22.27)
vVO _{2max} , km·h ⁻¹	17.51 (2.60)	17.93 (2.50)	17.90 (1.95)	19.83 (1.53)	20.33 (1.55)	19.80 (1.61)
Speed @ 2mmol·L, km·h ⁻¹	14.42 (2.58)	14.55 (2.55)	15.10 (1.96)	16.43 (1.63)	16.67 (1.24)	16.54 (1.52)
Speed @ 4mmol·L, km·h ⁻¹	16.20 (2.43)	16.15 (2.47)	16.82 (1.91)	18.23 (1.80)	18.24 (1.26)	18.01 (1.50)
TTE, s	370.25 (29.79)	365.50 (35.66)	352.86 (64.14)	350.86 (26.46)	369.43 (42.16)	373.33 (48.10)
RPE, Borg 6-20	12.88 (0.95)	12.68 (1.12)	12.29 (1.47)	13.89 (2.25)	12.96 (1.86)	12.95 (1.99)



The efficacy of iron treatment for endurance athletes: A meta-analysis

